FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Former McKinsey Exec Pleads Guilty in Opioid Case

The Justice Department says a former McKinsey executive pleaded guilty to knowingly destroying information central to the governments case against the...

latest-news-card-1
Human Drugs

Lillys Omvoh Wins Expanded Approval

FDA approves Eli Lillys Omvoh (mirikizumab-mrkz) for treating moderately to severely active Crohns disease in adults.

latest-news-card-1
Human Drugs

J&J Bladder Cancer Drug Under Review

FDA accepts for review a Johnson & Johnson NDA for TAR-200 (gemcitabine), an intravesical drug releasing system for treating certain patients with Bac...

latest-news-card-1
Human Drugs

Getinge/Maquet Recalls VasoView HemoPro 2 Devices

Getinge and its subsidiary Maquet Cardiovascular recall the VasoView HemoPro 2 (VH-4000 and VH-4001) Endoscopic Vessel Harvesting Systems due to the p...

latest-news-card-1
Federal Register

23 No-Longer-Marketed Generics Withdrawn

Federal Register notice: FDA withdraws approval of 23 ANDAs from multiple applicants after they told the agency that the drug products were no longer ...

latest-news-card-1
Human Drugs

Vanda Can Seek Tradipitant Hearing: FDA Notice

FDA proposes to deny a Vanda NDA for tradipitant and offers the company an opportunity to seek a commissioners hearing on the denial.

latest-news-card-1
Medical Devices

7 QS Issues at 3 Integra Facilities

FDA warns Integra Lifesciences about Quality System Regulation violations in the manufacturing of neurological and neurosurgical medical devices at th...

latest-news-card-1
Medical Devices

Hologic QS and MDR Violations

FDA warns Marlborough, MA-based Hologic about Quality System and Medical Device Reporting violations in its production of implantable radiographic mar...

latest-news-card-1
Federal Register

Novo Nordisk Wins Priority Review Voucher

Federal Register notice: FDA issues Novo Nordisk a priority review voucher for gaining approval for its hemophilia drug Alhemo (concizumab-mtci) last ...

latest-news-card-1
Federal Register

12 No-Longer-Marketed NDAs Withdrawn

Federal Register notice: FDA withdraws the approval of 12 NDAs from multiple applicants because they are no longer marketed.